

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 May 2002 (10.05.2002)

PCT

(10) International Publication Number  
WO 02/36826 A2

(51) International Patent Classification<sup>7</sup>: C12Q 1/68

(21) International Application Number: PCT/US01/42915

(22) International Filing Date:  
5 November 2001 (05.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/245,674 6 November 2000 (06.11.2000) US

(71) Applicants (for all designated States except US): GENE LOGIC, INC. [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). JAPAN TOBACCO, INC. [JP/JP]; 2-1 Toranomon 2-chome, Minato-ku, Tokyo 105-8422 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MUNGER, William, E. [US/US]; Gene Logic, Inc., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). KULKARNI,

Prakash [US/US]; c/o Gene Logic, Inc., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). GETZENBERG, Robert, H. [US/US]; University of Pittsburgh-Of the Commonwealth System of Higher Education, 200 Gardner Steel Conference Center, Thackery & O'Hara Streets, Pittsburgh, PA 15260 (US).


(74) Agents: TUSCAN, Michael, S. et al.; Morgan, Lewis & Bockius LLP, 1800 M Street, N.W., Washington, DC 20036-5869 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,

[Continued on next page]

(54) Title: DEL-1 AND BENIGN PROSTATIC HYPERPLASIA



#1505583<1-WA>

(57) Abstract: The invention relates generally to the changes in gene expression in Benign Prostatic Hyperplasia (BPH). The invention relates specifically to the human gene Del-1 which is differentially expressed in BPH compared to normal prostate tissue.



CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

**DEL-1 AND BENIGN PROSTATIC HYPERPLASIA**

**INVENTORS:** William E. Munger, Prakash Kulkarni and Robert H. Getzenberg

5   **RELATED APPLICATION**

This application is related to U.S. Provisional Application 60/245,674, filed November 6, 2000 which is herein incorporated by reference in its entirety.

**FIELD OF THE INVENTION**

10       The invention relates generally to the changes in gene expression in prostate tissue removed from male patients with benign prostatic hyperplasia (BPH). The invention specifically relates to a human gene which is differentially expressed in BPH tissue compared to normal prostate tissue.

15   **BACKGROUND OF THE INVENTION**

**Benign Prostatic Hyperplasia (BPH)**

BPH is the most common benign tumor in men over the age of 60. It is estimated that one in four men living to the age of 80 will require treatment for this disease. BPH is usually noted clinically after the age of 50, the incidence increasing with age, but as many  
20   as two thirds of men between the ages of 40 and 49 demonstrate histological evidence of the disease.

The anatomic location of the prostate at the bladder neck enveloping the urethra plays an important role in the pathology of BPH, including bladder outlet obstruction. Two prostate components are thought to play a role in bladder outlet obstruction. The first is the  
25   relatively increased prostate tissue mass. The second component is the prostatic smooth muscle tone.

The causative factors of BPH in man have been intensively studied (see Ziada *et al.*, *Urology* 53:1-6, 1999). In general, the two most important factors appear to be aging and the presence of functional testes. Although these factors appear to be key to the  
30   development of BPH, both appear to be nonspecific.

**Del-1 protein and gene**

A protein known as integrin-binding protein or Developmentally-regulated Endothelial cell Locus 1 protein (Del-1 or Dell) has been characterized as a matrix protein

having 3 epidermal growth factor (EGF)-like domains and 2 discoidin I / Factor VIII like domains. An RGD motif in the B-loop of the second EGF-like repeat is the likely site of interactions between Del-1 and integrin receptors, primarily  $\alpha v\beta 3$ . This matrix protein may have an autocrine function as it shows an endothelial cell-specific expression pattern and triggers  $\alpha v\beta 3$ -dependent cellular responses typical of these vascular cells. Through integrin-mediated signaling via the Ras-mitogen activated protein kinase (MAPK) pathway, Del-1 promotes endothelial cell adhesion, migration and can elicit either angiogenic and anti-angiogenic cellular responses under various experimental circumstances. Such activities support a role for Del-1 in complex processes of angiogenesis and vascular remodeling (Hidai *C et al.*, *Genes & Development* 12:21-33, 1998 and Penta *K et al.*, *J Biol Chem* 274:11101-9, 1999).

The Del-1 protein and gene have been described in US patent 5,874,562, US patent 5,877,281 and WO patent publication 96/40769. GenBank accession numbers for various forms of human and murine Del-1 are U70312 (human), U70313 (human, Z20 splice variant), AF31524 (major murine form) and AF 31525 (minor murine form, amino terminal truncation due to alternate splice site) all of which are herein incorporated by reference.

#### Molecular Changes in BPH

Little is known about the molecular changes in prostate cells associated with the development and progression of BPH. It has been demonstrated that the expression levels of a number of individual genes are changed compared to normal prostate cells. These changes in gene expression include a decreased level of Wilm's tumor gene (WT-1) and increased expression of insulin growth factor II (IGF-II) (Dong *et al.*, *J Clin Endocrin Metab* 82:2198-2203, 1997).

While the changes in the expression levels of a number of individual genes have been identified, the investigation of the global changes in gene expression has not been reported. Accordingly, there exists a need for the investigation of the changes in global gene expression levels as well as the need for the identification of new molecular markers associated with the development and progression of BPH. Furthermore, if intervention is expected to be successful in halting or slowing down BPH, means of accurately assessing the early manifestations of BPH need to be established. One way to accurately assess the early manifestations of BPH is to identify markers which are uniquely associated with disease progression. Likewise, the development of therapeutics to prevent or stop the progression of BPH relies on the identification of genes responsible for BPH growth and

function.

## SUMMARY OF THE INVENTION

The present invention is based on the discovery that the Del-1 gene is  
5 differentially expressed in BPH tissue compared to normal prostate tissue. The invention  
provides methods of diagnosing BPH in a patient comprising: acquiring a tissue, blood,  
urine or other sample from a subject; and determining the level of expression of a  
polypeptide or a nucleic acid molecule encoding Del-1 or a variant thereof. The  
invention further provides methods of diagnosing BPH wherein the Del-1 protein or  
10 variant thereof is encoded by (a) an isolated nucleic acid molecule that encodes the  
amino acid sequence of SEQ ID NO: 2; or (b) an isolated nucleic acid molecule which  
hybridizes to the complement of a nucleic acid molecule that encodes the amino acid  
sequence of SEQ ID NO: 2.

The invention further provides methods of identifying binding partners for a Del-  
15 1 protein or variant thereof, comprising: exposing Del-1 to a potential binding partner  
derived from prostate cells or tissue; and determining if the potential binding partner  
binds to Del-1, thereby identifying binding partners for the Del-1 protein or variant  
thereof. The cells of this method may be *in vitro*, may be obtained from human biopsy  
samples, or may be obtained from an animal model of prostate disease.

20 The invention further provides methods of identifying an agent which modulates  
the expression of a nucleic acid encoding a Del-1 protein or variant thereof, comprising:  
exposing prostate cells to the agent; and determining whether the agent modulates  
expression of said nucleic acid, thereby identifying an agent which modulates the  
expression of a nucleic acid encoding the Del-1 protein or variant thereof. The cells of  
25 this method may be *in vitro*, may be obtained from human biopsy samples, or may be  
obtained from an animal model of prostate disease.

The invention further provides methods of identifying an agent which modulates  
at least one activity of a Del-1 protein or variant thereof, comprising: exposing prostate  
cells to the agent; and determining whether the agent modulates at least one activity of  
30 the Del-1 protein or variant thereof, thereby identifying an agent which modulates at  
least one activity of the Del-1 protein or variant thereof. The cells of this method may be  
*in vitro*, may be obtained from human biopsy samples, or may be obtained from an  
animal model of prostate disease.

The invention further provides methods of modulating the expression of a nucleic

acid encoding a Del-1 protein or variant thereof, in a subject with benign prostatic hyperplasia, comprising: administering to the subject an effective amount of an agent which modulates the expression of a nucleic acid encoding the Del-1 protein or variant thereof.

- 5           The invention further provides methods of modulating at least one activity of a Del-1 protein or variant thereof, in a subject with benign prostatic hyperplasia, comprising: administering to the subject an effective amount of an agent which modulates at least one activity of a Del-1 protein or variant thereof.

## 10   BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1**       Figure 1 shows the expression of Del-1 (AA256268) in prostate biopsy samples from normal human patients (aged  $\leq 20$  years or 30-50 years) and BPH patients, including BPH samples from individuals without symptoms, samples from BPH patients without symptoms who were diagnosed with prostate cancer, and samples from  
15   BPH patients with symptoms. In all cases, the subregion of the prostate analyzed was the transitional zone. The group average standard deviation is shown to the right of individual values within each disease group, and is also shown in Figure 3 for comparison with other normal tissues.

**Figure 2**       Figure 2 shows the tissue distribution of RNA encoding the protein of Del-1 (about 5.0 kb) as analyzed by Northern blot in human heart, brain, spleen, lung, liver, smooth muscle, kidney and testes (lanes 1-8, respectively). Lane M contains RNA markers, indicated by small dots (4.4 and 7.5 kb markers are labeled).  
20

**Figure 3**       Figure 3 shows an electronic Northern, in which the expression level of AA256268 was measured across a panel of normal tissues and tissues from subtypes of BPH patients (see Figure 1) using the Affymetrix human Hu35KsubA GeneChip set. For each tissue type, the mean SDM is shown as a horizontal bar graph for samples obtained from 3 or more normal individuals.  
25

**Figure 4**       Figure 4 shows the results of semi-quantitative PCR for the expression of AA256268 in various tissues. Upper panel of the gel: 25 cycles. Lower gel  
30   panel: 30 cycles. Double lanes are shown for each tissue: the primer pair F156-177/R759-770 were used for the first lane per tissue, and primers F182-201/R780-801 were used for the second lane per tissue. Lanes: M) 100 bp ladder; 1) heart; 2) brain; 3) leukocytes; 4) lung; 5) liver; 6) fetal brain; 7) kidney; 8) spleen; 9) placenta; 10) BRF 55; 11) glomeruli; and 12) osteoblast.

**Figure 5** Figure 5 is a hydrophobicity plot (PEPLOT) of AA256268. Analysis was done using the methods of Goldman *et al.* and of Kyte-Doolittle.

## **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

### **I. General Description**

The present invention is based in part on the identification of a gene family that is differentially expressed in human BPH tissue compared to normal human prostate tissue.

This gene family corresponds to a human gene that encodes a protein of 480 amino acids (Del-1 or AA256268). The gene that encodes this human protein is also present in mice, and may be found in other animal species, particularly mammalian species.

The Del-1 protein or variants thereof can serve as a targets for agents that modulate gene expression or activity in prostate cells. For example, agents may be identified that modulate biological processes associated with prostate growth, including the hyperplastic process of BPH.

The present invention is further based on the development of methods for isolating binding partners that bind to the Del-1 protein or variants thereof in prostate cells. Additionally, the Del-1 protein or variants thereof provide novel targets for the screening of synthetic small molecules and combinatorial or naturally occurring compound libraries to discover novel therapeutics to regulate prostate function.

### **II. Specific Embodiments**

#### **A. The Protein Associated with BPH**

The methods of the present invention measure the level of expression of a nucleic acid molecule encoding a Del-1 protein or a variant thereof. As used herein, "Del-1" refers, in part, to the human amino acid sequence depicted in SEQ ID NO: 2, and "protein" or "polypeptide" refers, in part, to a protein that has the human amino acid sequence depicted in SEQ ID NO: 2. The term "variant" in the phrase "a Del-1 protein or a variant thereof" refers to any naturally occurring allelic variant, splicing variant or protein that has a slightly different amino acid sequence than that specifically recited above. Allelic variants, though possessing a slightly different amino acid sequence than that recited above, will still have the same or similar biological functions associated with the Del-1 protein.

The variants of the Del-1 protein are further defined to include insertion, deletion or amino acid substitution variants of the sequence set forth in SEQ ID NO: 2. Insertion

variants are those in which one or more amino acid residues has been inserted N- or C-terminal to, or within, the disclosed sequence. The substitution, insertion or deletion of one or more amino acids may or may not be a conservative variation. As used herein, a substitution, insertion or deletion is conservative if the alterations in the amino acid sequence do not adversely affect the biological functions of the protein. A substitution, insertion or deletion is said to adversely affect the protein when the altered sequence prevents or disrupts a biological function associated with the protein. For example, the overall charge, structure or hydrophobic/hydrophilic properties of the protein can be altered without adversely affecting a biological activity. Accordingly, the amino acid sequence can be altered, for example to render the peptide more hydrophobic or hydrophilic, without adversely affecting the biological activities of the protein.

Ordinarily, the allelic variants, the conservative substitution variants, and the members of the protein family, will have an amino acid sequence having at least about 50%, 60%, 70% or 75% amino acid sequence identity with the sequence set forth in SEQ ID NO: 2, more preferably at least about 80%, even more preferably at least about 90%, and most preferably at least about 95% sequence identity. Identity or homology with respect to such sequences is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the known peptides, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity (see section B for the relevant parameters). Fusion proteins, or N-terminal, C-terminal or internal extensions, deletions, or insertions into the peptide sequence shall not be construed as affecting homology.

The Del-1 protein variants also include fragments of the protein disclosed in SEQ ID NO: 2, and the related variants discussed herein, having a consecutive sequence of at least about 3, 4, 5, 6, 10, 15, 20, 25, 30, 35 or more amino acid residues of these proteins; amino acid sequence variants wherein one or more amino acid residues has been inserted N- or C-terminal to, or within, the disclosed coding sequence; and amino acid sequence variants of the disclosed sequence, or their fragments as defined above, that have been substituted by another residue. Such fragments, also referred to as peptides or polypeptides, may contain antigenic regions, functional regions of the protein identified as regions of the amino acid sequence which correspond to known protein domains, as well as regions of pronounced hydrophilicity. The regions are all easily identifiable by using commonly available protein sequence analysis software such as MacVector



(Oxford Molecular).

As used herein, the family of proteins and variants related to the human amino acid sequence of SEQ ID NO: 2 also refers to proteins that have been isolated from organisms in addition to humans. The methods used to identify and isolate other members of the family of proteins related to these proteins are well known (see Sambrook *et al.*, Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Contemplated variants further include those containing predetermined mutations by, *e.g.*, homologous recombination, site-directed or PCR mutagenesis, and the corresponding proteins of other animal species, including but not limited to rabbit, mouse, rat, porcine, bovine, ovine, equine and non-human primate species, and the alleles or other naturally occurring variants of the family of proteins; and derivatives wherein the protein has been covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid (for example a detectable moiety such as an enzyme or radioisotope).

The level of expression of members of the family of Del-1 proteins can be measured in terms of the nucleotide product(s) of transcription, for example including but not limited to total RNA or mRNA, or in terms of the protein product(s) of translation, including but not limited to the protein at any stage before or after one or more post-translational cellular events including but not limited to, folding, cleavage, glycosylation and phosphorylation, binding (*e.g.* to a receptor or an antibody), labeling, purification or isolation.

As described below, members of the family of proteins can be used: (1) to identify agents which modulate at least one activity of the protein; (2) to identify binding partners for the protein, and (3) as a therapeutic agent or target.

## B. Nucleic Acid Molecules

The methods of the present invention measure the level of expression of a nucleic acid molecule that encodes the protein having SEQ ID NO: 2 and the related protein variants herein described. As used herein, "nucleic acid" is defined as RNA or DNA that encodes a protein or peptide as defined above, or that hybridizes to the complement of a nucleic acid that encodes the amino acid sequence of SEQ ID NO: 2 and remains stably bound to it under appropriate stringency conditions, encodes a polypeptide sharing at least about 50%, 60%, 70% or 75% sequence identity, preferably at least about 80%,

more preferably at least about 85%, and even more preferably at least about 90% or 95% or more identity with the Del-1 peptide sequence or variants thereof, or exhibits at least about 50%, 60%, 70%, 80%, 90% or 95% or more nucleotide sequence identity over the open reading frame of SEQ ID NO: 1. Specifically contemplated are RNA molecules  
5 such as total RNA and mRNA.

Homology or identity at the nucleotide or amino acid sequence level is determined by BLAST (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs blastp, blastn, blastx, tblastn and tblastx (Karlin *et al.*, *Proc Natl Acad Sci USA* 87:2264-2268, 1990 and Altschul, *J Mol Evol* 36:290-300,  
10 1993, fully incorporated by reference) which are tailored for sequence similarity searching. The approach used by the BLAST program is to first consider similar segments between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected threshold of significance. For a discussion of  
15 basic issues in similarity searching of sequence databases, see Altschul *et al.*, *Nature Genetics* 6:119-129, 1994, which is fully incorporated by reference. The search parameters for histogram, descriptions, alignments, expect (*i.e.*, the statistical significance threshold for reporting matches against database sequences), cutoff, matrix and filter are at the default settings. The default scoring matrix used by blastp, blastx,  
20 tblastn, and tblastx is the BLOSUM62 matrix (Henikoff *et al.*, *Proc Natl Acad Sci USA* 89:10915-10919, 1992, fully incorporated by reference). For blastn, the scoring matrix is set by the ratios of M (*i.e.*, the reward score for a pair of matching residues) to N (*i.e.*, the penalty score for mismatching residues), wherein the default values for M and N are 5 and -4, respectively. Four blastn parameters were adjusted as follows: Q=10 (gap  
25 creation penalty); R=10 (gap extension penalty); wink=1 (generates word hits at every wink<sup>th</sup> position along the query); and gapw=16 (sets the window width within which gapped alignments are generated). The equivalent Blastp parameter settings were Q=9; R=2; wink=1; and gapw=32. A Bestfit comparison between sequences, available in the GCG package version 10.0, uses DNA parameters GAP=50 (gap creation penalty) and  
30 LEN=3 (gap extension penalty) and the equivalent settings in protein comparisons are GAP=8 and LEN=2.

"Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate/0.1% SDS at 50°C., or (2) employ during hybridization a denaturing agent such as formamide,

for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C. Another example is hybridization in 50% formamide, 5× SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2× SSC and 0.1% SDS. A skilled artisan can readily determine and vary the stringency conditions appropriately to obtain a clear and detectable hybridization signal. Preferred molecules are those that hybridize under the above conditions to the complement of SEQ ID NO: 1 and which encode a functional protein. Even more preferred hybridizing molecules are those that hybridize under the above conditions to the complement strand of the open reading frame of SEQ ID NO: 1.

A nucleic acid molecule encoding a Del-1 protein, or a variant as described above, includes fragments of the encoding nucleic acid molecule. As used herein, a fragment of an encoding nucleic acid molecule refers to a small portion of the entire protein coding sequence.

The size of the fragment will be determined by the intended use. For example, if the fragment is chosen so as to encode an active portion of the protein, the fragment will need to be large enough to encode the functional region(s) of the protein. For instance, fragments which encode peptides corresponding to predicted antigenic regions may be prepared (see Figure 5).

If the fragment is to be used as a nucleic acid probe or PCR primer, then the fragment length is chosen so as to obtain a relatively small number of false positives during probing/priming (see the discussion in Section G).

Fragments of the nucleic acid molecules encoding a Del-1 protein or a variant thereof, (*i.e.*, synthetic oligonucleotides) that are used as probes or specific primers for the polymerase chain reaction (PCR), or to synthesize gene sequences encoding Del-1 protein or a variant thereof, can easily be synthesized by chemical techniques, for example, the phosphoramidite method of Matteucci *et al.* (*J Am Chem Soc* 103:3185-3191, 1981) or using automated synthesis methods. In addition, larger DNA segments can readily be prepared by well known methods, such as synthesis of a group of oligonucleotides that define various modular segments of the gene, followed by ligation of oligonucleotides to build the complete modified gene.

The encoding nucleic acid molecules of the present invention may further be

modified so as to contain a detectable label for diagnostic and probe purposes. A variety of such labels are known in the art and can readily be employed with the encoding molecules herein described. Suitable labels include, but are not limited to, biotin, radiolabeled nucleotides and the like. A skilled artisan can readily employ any such label to obtain labeled variants of the nucleic acid molecules encoding a Del-1 protein or a variant as described above.

### C. Methods to Identify Binding Partners

Another embodiment of the present invention provides methods for isolating and identifying binding partners of Del-1 protein or a variant thereof. In general, a Del-1 protein or a Del-1 variant is mixed with a potential binding partner in an extract of a cell under conditions that allow the association of potential binding partners with the protein. After mixing, peptides, polypeptides, proteins or other molecules that have become associated with a Del-1 protein or variant of the invention are separated from the mixture. The binding partner that bound to the protein of the invention can then be removed and further analyzed. To identify and isolate a binding partner, the entire Del-1 protein, for instance a protein comprising the entire amino acid sequence of SEQ ID NO: 2, can be used. Alternatively, a fragment of the protein can be used.

As used herein, a cellular extract refers to a preparation or fraction which is made from a lysed or disrupted prostate cell. The preferred source of cellular extracts will be cells derived from human prostate tissue or cells, for instance, biopsy tissue or tissue culture cells from BPH patients. Animal models of prostate disease, as are known to persons of ordinary skill in the art, are another source of cells for cellular extract. For example, see Coffey DS and Walsh PC, "Clinical and experimental studies of benign prostatic hyperplasia," *Urol Clin North Am* 17:461, 1990 (canine); Brendler CB *et al.*, "Spontaneous benign prostatic hyperplasia in the beagle," *J Clin Invest* (1983) 71:1114, 1983; Winter ML *et al.*, "Induction of benign prostatic hyperplasia in intact dogs by near-physiological levels of 5-alpha-dihydrotestosterone and 17-beta-estradiol," *Prostate* 26: 325, 1995; Banerjee PP *et al.*, "Age-dependent and lobe-specific spontaneous hyperplasia in the Brown Norway rat prostate," *Biol Reprod* 59: 1163, 1998; Van Coppenolle F *et al.*, "Pharmacological effects of the lipidosterolic extract of *Serenoa repens* (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride," *Prostate* 43:49, 2000; Steiner MS *et al.*, "The chimpanzee as a model of human benign prostatic hyperplasia," *J Urol* 162:1454, 1999; and Shishido

T *et al.*, *Nippon Hinyokika Gakkai Zasshi* 91:459, 2000 (guinea pig).

Alternatively, cellular extracts may be prepared from normal human prostate tissue or available cell lines, particularly prostate derived cell lines.

A variety of methods can be used to obtain an extract of a cell. Cells can be  
5 disrupted using either physical or chemical disruption methods. Examples of physical  
disruption methods include, but are not limited to, sonication and mechanical shearing.  
Examples of chemical lysis methods include, but are not limited to, detergent lysis and  
enzyme lysis. Extracts may be further manipulated before use in the methods of the  
invention, for example by fractionation or by other types of purification. A skilled  
10 artisan can readily adapt methods for preparing cellular extracts in order to obtain  
extracts for use in the present methods.

Once an extract of a cell is prepared, the extract is mixed with the Del-1 protein  
or a variant thereof under conditions in which association of the protein with the binding  
partner can occur. A variety of conditions can be used, the most preferred being  
15 conditions that closely resemble conditions found in the cytoplasm of a human cell.  
Features such as osmolarity, pH, temperature, and the concentration of cellular extract  
used, can be varied to optimize the association of the protein with the binding partner.

After mixing under appropriate conditions, the bound complex is separated from  
the mixture. A variety of techniques can be utilized to separate the mixture. For  
20 example, antibodies specific to a Del-1 protein or a variant thereof can be used to  
immunoprecipitate the binding partner complex. Alternatively, standard chemical  
separation techniques such as chromatography and density/sediment centrifugation can  
be used.

After removal of non-associated cellular constituents found in the extract, the  
25 binding partner can be dissociated from the complex using conventional methods. For  
example, dissociation can be accomplished by altering the salt concentration or pH of the  
mixture.

To aid in separating associated binding partner pairs from the mixed extract, the  
Del-1 protein or a variant thereof can be immobilized on a solid support. For example,  
30 the protein can be attached to a nitrocellulose matrix or acrylic beads. Attachment of the  
protein to a solid support aids in separating peptide/binding partner pairs from other  
constituents found in the extract. The identified binding partners can be either a single  
protein or a complex made up of two or more proteins. Alternatively, binding partners  
may be identified using a Far-Western assay according to the procedures of Takayama *et*

*al.*, *Methods Mol Biol* 69:171-184, 1997 or Sauder *et al.*, *J Gen Virol* 77:991-996, 1996, or identified through the use of epitope tagged proteins or GST fusion proteins.

Alternatively, the nucleic acid molecules encoding a Del-1 protein or a variant thereof can be used in a yeast two-hybrid system. The yeast two-hybrid system has been used to identify other protein partner pairs and can readily be adapted to employ the nucleic acid molecules herein described.

#### **D. Methods to Identify Agents that Modulate the Expression a Nucleic Acid Encoding the Proteins Associated with BPH**

Another embodiment of the present invention provides methods for identifying agents that modulate the expression of a nucleic acid encoding a Del-1 protein, such as a protein having the amino acid sequence of SEQ ID NO: 2, or a variant thereof. Such assays may utilize any available means of monitoring for changes in the expression level of the nucleic acids encoding Del-1 protein or a variant thereof. As used herein, an agent is said to modulate the expression of a nucleic acid encoding the Del-1 protein or a variant thereof, if it is capable of up- or down-regulating expression of the nucleic acid in a cell.

In one assay format, cell lines associated with BPH, that contain reporter gene fusions between part or all of the open reading frame defined by nucleotides 406-1845 of SEQ ID NO: 1, and/or the 5' and/or 3' regulatory sequences and any assayable fusion partner may be prepared. Numerous assayable fusion partners are known and readily available including the firefly luciferase gene and the gene encoding chloramphenicol acetyltransferase (Alam *et al.*, *Anal Biochem* 188:245-254, 1990). Cell lines containing the reporter gene fusions are then exposed to the agent to be tested under appropriate conditions and time. Differential expression of the reporter gene between samples exposed to the agent and control samples identifies agents which modulate the expression of a nucleic acid encoding the Del-1 protein, such as a protein having the amino acid sequence of SEQ ID NO: 2, or a variant thereof.

Additional assay formats may be used to monitor the ability of the agent to modulate the expression of a nucleic acid encoding a Del-1 protein of the invention, such as the protein having the amino acid sequence of SEQ ID NO: 2, or a variant thereof. For instance, mRNA expression may be monitored directly by hybridization to the nucleic acids encoding the Del-1 protein or a variant thereof. Prostate cell lines or tissues or cell lines associated with BPH are exposed to the agent to be tested under appropriate

conditions and time and total RNA or mRNA is isolated by standard procedures such those disclosed in Sambrook *et al.*, (*supra*).

Probes to detect differences in RNA expression levels between cells exposed to the agent and control cells may be prepared from the nucleic acids encoding a Del-1 protein, such as a protein having the amino acid sequence of SEQ ID NO: 2, or a variant thereof. It is preferable, but not necessary, to design probes which hybridize only with target nucleic acids under conditions of high stringency. Only highly complementary nucleic acid hybrids form under conditions of high stringency. Accordingly, the stringency of the assay conditions determines the amount of complementarity which should exist between two nucleic acid strands in order to form a hybrid. Stringency should be chosen to maximize the difference in stability between the probe:target hybrid and probe:non-target hybrids.

Probes may be designed from the nucleic acids encoding a Del-1 protein or a variant thereof through methods known in the art. For instance, the G+C content of the probe and the probe length can affect probe binding to its target sequence. Methods to optimize probe specificity are commonly available in Sambrook *et al.*, (*supra*) or Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Co., 1995.

Hybridization conditions are modified using known methods, such as those described by Sambrook *et al.* and Ausubel *et al.* as required for each probe.

Hybridization of total cellular RNA or RNA enriched for polyA RNA can be accomplished in any available format. For instance, total cellular RNA or RNA enriched for polyA RNA can be affixed to a solid support and the solid support exposed to at least one probe comprising at least one, or part of one, of the sequences of Del-1 protein or a variant thereof under conditions in which the probe will specifically hybridize. Alternatively, nucleic acid fragments comprising at least one, or part of one, of the sequences of Del-1 protein or a variant thereof can be affixed to a solid support, such as a silicon chip or a porous glass chip or wafer. The wafer can then be exposed to total cellular RNA or polyA RNA from a sample under conditions in which the affixed sequences will specifically hybridize. Such solid supports and hybridization methods are widely available, for example, those disclosed by Beattie, WO 95/11755 (1995). By examining for the ability of a given probe to specifically hybridize to an RNA sample from an untreated cell population and from a cell population exposed to the agent, agents which up or down regulate the expression of a nucleic acid encoding the protein having the sequence of SEQ ID NO: 2 are identified.

Hybridization for qualitative and quantitative analysis of mRNAs may also be carried out by using a RNase Protection Assay (*i.e.*, RPA, see Ma *et al.*, *Methods* 10: 273-238, 1996). Briefly, an expression vehicle comprising cDNA encoding the gene product and a phage specific DNA dependent RNA polymerase promoter (*e.g.*, T7, T3 or SP6 RNA polymerase) is linearized at the 3' end of the cDNA molecule, downstream from the phage promoter, wherein such a linearized molecule is subsequently used as a template for synthesis of a labeled antisense transcript of the cDNA by *in vitro* transcription. The labeled transcript is then hybridized to a mixture of RNA isolated from cells associated with BPH (*i.e.*, total or fractionated mRNA), by incubation at 45°C overnight in a buffer comprising 80% formamide, 40 mM Pipes, pH 6.4, 0.4 M NaCl and 1 mM EDTA. The resulting hybrids are then digested in a buffer comprising 40 µg/ml ribonuclease A and 2 µg/ml ribonuclease. After deactivation and extraction of extraneous proteins, the samples are loaded onto urea/polyacrylamide gels for analysis.

In another assay to identify agents which effect the expression of the instant gene products, cells or cell lines associated with BPH are first identified which physiologically express Del-1 protein or a variant thereof (*e.g.*, by using assays of tissue distribution via Northern blot, although RPAs may serve the identical purpose of expression selection). Cells and/or cell lines so identified would be expected to comprise the necessary cellular machinery such that the fidelity of modulation of the transcriptional apparatus is maintained with regard to exogenous contact of agent with appropriate surface transduction mechanisms and/or the cytosolic cascades. Further, such cells or cell lines are transduced or transfected with an expression vehicle (*e.g.*, a plasmid or viral vector) construct comprising an operable non-translated 5'-promoter-containing end of the structural gene encoding the instant gene products fused to one or more antigenic fragments, which are peculiar to the Del-1 protein or variant, wherein said fragments are under the transcriptional control of said promoter and are expressed as polypeptides whose molecular weight can be distinguished from the naturally occurring polypeptides or may further comprise an immunologically distinct tag or other detectable marker. Such a process is well known in the art (see Sambrook *et al.*, *supra*).

The prostate cell lines or tissues, or cells or cell lines associated with BPH, transduced or transfected as outlined above, are then contacted with agents under appropriate conditions. For example, the agent comprises a pharmaceutically acceptable excipient and is contacted with cells comprised in an aqueous physiological buffer such as phosphate buffered saline (PBS) at physiological pH, Eagles balanced salt solution



(BSS) at physiological pH, PBS or BSS comprising serum or conditioned media comprising PBS or BSS and/or serum incubated at 37°C. Said conditions may be modulated as deemed necessary by one of skill in the art. Subsequent to contacting the cells with the agent, said cells are disrupted and the polypeptides of the lysate are  
5 fractionated such that a polypeptide fraction is pooled and contacted with an antibody to be further processed by immunological assay (*e.g.*, ELISA, immunoprecipitation or Western blot). The pool of proteins isolated from the "agent-contacted" sample is then compared with a control sample where only the excipient is contacted with the cells, and an increase or decrease in the immunologically generated signal from the "agent-  
10 contacted" sample compared to the control is used to distinguish the effectiveness of the agent.

**E. Methods to Identify Agents that Modulate the Levels of or at Least One Activity of the BPH-Associated Proteins**

15 Another embodiment of the present invention provides methods for identifying agents that modulate at least one activity of a Del-1 protein, such as the protein having the amino acid sequence of SEQ ID NO: 2, or a variant thereof. Such methods or assays utilize cells associated with BPH, and may utilize any means of monitoring or detecting the desired activity. For example, the method or assay could measure an activity such as  
20 binding to or clustering of endothelial cell receptors of the integrin family such as the  $\alpha v \beta 3$  receptor, the formation of focal complexes or recruitment of talin and vinculin into these complexes, the phosphorylation of proteins within the focal complexes (*e.g.* of p125<sup>FAK</sup>, MAPK or Shc), endothelial cell adhesion or migration, angiogenesis or vascular formation (Penta K *et al.*, *J Biol Chem* 274:11101-11109, 1999).

25 In one format, the relative amounts of a Del-1 protein, or a variant thereof, between a cell population that has been exposed to the agent to be tested compared to an un-exposed control cell population may be assayed. In this format, probes such as specific antibodies are used to monitor the differential expression of the protein in the different cell populations. Cell lines or populations are exposed to the agent to be tested  
30 under appropriate conditions and time. Cellular lysates may be prepared from the exposed cell line or population and a control, unexposed cell line or population. The cellular lysates are then analyzed with the probe.

Antibody probes are prepared by immunizing suitable mammalian hosts in appropriate immunization protocols using a sequence of six or more consecutive amino

acids from the Del-1 protein or a variant thereof, or if desired, or if required, to enhance immunogenicity, the selected peptide sequence may be conjugated to suitable carriers. Methods for preparing immunogenic conjugates with carriers such as BSA, KLH, or other carrier proteins are well known in the art. In some circumstances, direct  
5 conjugation using, for example, carbodiimide reagents may be effective; in other instances linking reagents such as those supplied by Pierce Chemical Co. (Rockford, IL), may be desirable to provide accessibility to the hapten. The hapten peptides can be extended at either the amino or carboxy terminus with a cysteine residue or interspersed with cysteine residues, for example, to facilitate linking to a carrier. Administration of  
10 the immunogens is conducted generally by injection over a suitable time period and with use of suitable adjuvants, as is generally understood in the art. During the immunization schedule, titers of antibodies are taken to determine adequacy of antibody formation.

While the polyclonal antisera produced in this way may be satisfactory for some applications, the use of monoclonal preparations is preferred for pharmaceutical  
15 compositions. Immortalized cell lines which secrete the desired monoclonal antibodies may be prepared using the standard method of Kohler and Milstein (*Nature* 256:495-497, 1975) or modifications which effect immortalization of lymphocytes or spleen cells, as is generally known. The immortalized cell lines secreting the desired antibodies are screened by immunoassay in which the antigen is the peptide hapten, polypeptide or  
20 protein. When the appropriate immortalized cell culture secreting the desired antibody is identified, the cells can be cultured either *in vitro* or by production in ascites fluid.

The desired monoclonal antibodies are then recovered from the culture supernatant or from the ascites supernatant. Fragments of the monoclonals or the polyclonal antisera which contain the immunologically significant portion can be used as  
25 antagonists, as well as the intact antibodies. Use of immunologically reactive fragments, such as the Fab, Fab', or F(ab')<sub>2</sub> fragments is often preferable, especially in a therapeutic context, as these fragments are generally less immunogenic than the whole immunoglobulin.

The antibodies or fragments may also be produced, using current technology, by  
30 recombinant means. Antibody regions that bind specifically to the desired regions of the protein can also be produced in the context of chimeras with multiple species origin, such as humanized antibodies.

Agents that are assayed in the above method can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected

when the agent is chosen randomly without considering the specific sequences involved in the association of a Del-1 protein (or a variant thereof) alone or with its associated substrates, binding partners, etc. An example of randomly selected agents is the use a chemical library or a peptide combinatorial library, or a growth broth of an organism.

5 As used herein, an agent is said to be rationally selected or designed when the agent is chosen on a nonrandom basis which takes into account the sequence of the target site and/or its conformation in connection with the agent's action. As described in the Examples, there are proposed binding motifs, hydroxylation and other consensus sites in the protein having SEQ ID NO: 2. Agents can be rationally selected or rationally  
10 designed by utilizing the peptide sequences that make up these sites. For example, a rationally selected peptide agent can be a peptide whose amino acid sequence is identical to an EGF-like domain or hydroxylation site in SEQ ID NO: 2, as described in the Examples.

The agents assayed using the method of the present invention can be, as  
15 examples, peptides, small molecules, vitamin derivatives, as well as carbohydrates. Dominant negative proteins, DNAs encoding these proteins, antibodies to these proteins, peptide fragments of these proteins or mimics of these proteins may be introduced into cells to affect function. "Mimic" used herein refers to the modification of a region or several regions of a peptide molecule to provide a structure chemically different from the  
20 parent peptide but topographically and functionally similar to the parent peptide (see Grant GA. in: Meyers (ed.) Molecular Biology and Biotechnology, pp. 659-664, VCH Publishers, New York, 1995). A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents that can be assayed in the methods of the present invention.

25 The peptide agents assayed in the methods of the invention can be prepared using standard solid phase (or solution phase) peptide synthesis methods, as is known in the art. In addition, the DNA encoding these peptides may be synthesized using commercially available oligonucleotide synthesis instrumentation and produced recombinantly using standard recombinant production systems. The production using  
30 solid phase peptide synthesis is necessitated if non-gene-encoded amino acids are to be included.

Another class of agents that may be assayed in the methods of the present invention are antibodies immunoreactive with critical positions within a Del-1 protein or variant thereof. Antibody agents are obtained by immunization of suitable mammalian

subjects with peptides, containing as antigenic regions, those portions of the protein intended to be targeted by the antibodies.

**F. Uses for Agents that Modulate Expression or at Least One Activity of the BPH-Associated Proteins**

Another embodiment of the present invention provides methods for modulating the expression or at least one activity of a Del-1 protein or a variant thereof, in a subject with benign prostatic hyperplasia. As provided in the Examples, the nucleic acid encoding the Del-1 protein having the amino acid sequence of SEQ ID NO: 2 is differentially expressed in BPH tissue compared to normal tissue. Agents that modulate or up- or down-regulate the expression of the Del-1 protein (or a variant thereof) or agents, such as agonists or antagonists that modulate at least one activity of the protein (or a variant thereof), may be used to modulate biological and pathologic processes associated with the protein's function and activity in a subject with BPH.

As used herein, a subject can be any mammal. The term "mammal" is defined as an individual belonging to the class Mammalia. The agent is particularly useful in the treatment of human subjects.

Pathological processes refer to a category of biological processes which produce a deleterious effect in BPH. For example, expression of a Del-1 protein (or a variant thereof) may be associated with prostate cell growth or hyperplasia. As used herein, an agent is said to modulate a pathological process when the agent reduces the degree or severity of the process. For instance, BPH may be prevented or disease progression modulated by the administration of agents which up- or down-regulate or modulate in some way the expression or at least one activity of a Del-1 protein or variant thereof.

Modulatory agents used in the methods of the present invention can be provided alone, or in combination with other agents that modulate a particular pathological process. For example, an agent of the present invention can be administered in combination with other known drugs. As used herein, two agents are said to be administered in combination when the two agents are administered simultaneously or are administered independently in a fashion such that the agents will act at the same time.

The agents used in methods of the present invention can be administered via parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the

recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

The present invention further provides methods using compositions containing one or more agents which modulate expression or at least one activity of a Del-1 protein  
5 or a variant thereof, in a subject with benign prostatic hyperplasia. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise 0.1 to 100  $\mu\text{g/kg}$  body wt. The preferred dosages comprise 0.1 to 10  $\mu\text{g/kg}$  body wt. The most preferred dosages comprise 0.1 to 1  $\mu\text{g/kg}$  body wt.

10 In addition to the pharmacologically active agent, the compositions used in the methods of the present invention may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically for delivery to the site of action. Suitable formulations for parenteral administration include aqueous solutions  
15 of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, *e.g.*, sesame oil, or synthetic fatty acid esters, *e.g.*, ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances which increase the viscosity of the  
20 suspension, and the substances may include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers. Liposomes can also be used to encapsulate the agent for delivery into the cell.

The pharmaceutical formulation for systemic administration according to the  
25 invention may be formulated for enteral, parenteral or topical administration. Indeed, all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient.

Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or inhalations and  
30 controlled release forms thereof.

In practicing the methods of this invention, the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this invention may be coadministered along with other compounds typically prescribed for these conditions

according to generally accepted medical practice. The compounds of this invention can be utilized *in vivo*, ordinarily in mammals, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*.

## 5 G. Diagnostic Methods

As the gene for Del-1 is differentially expressed in BPH tissue compared to normal prostate tissue, the level of expression of Del-1 protein or variants thereof, and of the genes that encode these proteins, may be used to diagnose or monitor BPH, prostate function, or to track disease progression.

10 One means of diagnosing BPH using the nucleic acid molecules encoding Del-1 protein (or variants thereof) or protein molecules themselves involves obtaining prostate tissue from living subjects. Obtaining tissue samples from living sources is problematic for tissues such as prostate. However, due to the nature of the treatment paradigms for BPH, biopsy may be necessary. Methods of the invention may involve treatment of  
15 tissues with collagenases or other proteases to make the tissue amenable to cell lysis (Semenov *et al.*, *Biull Eksp Biol Med* 104, 113-116, 1987). Further, it is possible to obtain biopsy samples from different regions of the prostate for analysis. When possible, urine, blood, peripheral lymphocytes or other tissue samples may be used as the tissue sample in the assay.

20 The use of molecular biological tools has become routine in forensic technology. For example, nucleic acid probes may be used to determine the expression of a nucleic acid molecule comprising all or at least part of the sequence of Del-1 (SEQ ID NO: 1) or variants thereof, as described above, in forensic/pathology specimens. Further, nucleic acid assays may be carried out by any means of conducting a transcriptional profiling  
25 analysis. In addition to nucleic acid analysis, forensic methods of the invention may target a Del-1 protein, such as the protein comprising SEQ ID NO: 2, or variants described above, to determine up- or down-regulation of the genes (Shiverick *et al.*, *Biochim Biophys Acta* 393:124-133, 1975).

Assays to detect nucleic acid or protein molecules of the invention may be in any  
30 available format. Typical assays for nucleic acid molecules include hybridization or PCR based formats. In one assay format, mRNA expression may be monitored directly by hybridization to the nucleic acids probes. Total RNA or mRNA is isolated from patient samples by standard procedures such those disclosed in Sambrook *et al.*, (*supra*). See section D for a discussion of commonly available assay formats and Example 3 for

an example of a PCR based assay. In preferred embodiments, assays are carried-out with appropriate controls.

Typical assays for the detection of a Del-1 protein or variant thereof include the use of antibody probes in any available format such as *in situ* binding assays, etc. (see Harlow & Lane, Antibodies - A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988. For example, in *in vitro* assays, cells from test samples are disrupted and the polypeptides of the lysate are fractionated such that a polypeptide fraction is pooled and contacted with an antibody to be further processed by immunological assay (e.g., ELISA, immunoprecipitation or Western blot). The pool of proteins isolated from the test sample will be compared with a control sample and an increase or decrease in the immunologically generated signal from the test sample compared to the control will be used to distinguish the effectiveness of the agent.

The above methods may also be used in other diagnostic protocols, including protocols and methods to detect disease states in other tissues or organs, for example the tissues in which gene expression is detected (see Figure 2 and Figure 3).

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, practice the claimed methods of the present invention. The following working examples, therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

## EXAMPLES

### Example 1

#### 25 Identification of Differentially Expressed BPH mRNA

Human tissue was obtained from the transitional zone of the prostate in biopsy samples from normal individuals and from patients with BPH. BPH was defined histologically in all samples. Normal tissue and asymptomatic BPH samples came from individuals who died of trauma, and did not report symptoms. Patients having BPH with symptoms were defined as those with a need for frequent urination; in these patients a radical prostatectomy had been performed. Prostate cancer patients provided age-matched tissue samples for symptomatic BPH patients, but were without symptoms and without cancer in the transitional zone under examination.

Microarray sample preparation was conducted with minor modifications,

following the protocols set forth in the Affymetrix GeneChip® Expression Analysis Manual. Frozen tissue was ground to a powder using a Spex Certiprep 6800 Freezer Mill. Total RNA was extracted with Trizol® (GibcoBRL) utilizing the manufacturer's protocol. The total RNA yield for each sample was 200-500 g per 300 mg tissue weight.

5 mRNA was isolated using the Oligotex mRNA Midi kit® (Qiagen) followed by ethanol precipitation. Double stranded cDNA was generated from mRNA using the SuperScript Choice® system (GibcoBRL). First strand cDNA synthesis was primed with a T7-(dT24) oligonucleotide. The cDNA was phenol-chloroform extracted and ethanol precipitated to a final concentration of 1 g/l. From 2 g of cDNA, cRNA was synthesized using

10 Ambion's T7 MegaScript in vitro Transcription Kit®.

To biotin label the cRNA, nucleotides Bio-11-CTP and Bio-16-UTP (Enzo Diagnostics) were added into the reaction. Following a 37C incubation for six hours, impurities were removed from the labeled cRNA following the RNaseasy Mini kit protocol (Qiagen). cRNA was fragmented (5' fragmentation buffer consisting of 200

15 mM Tris-acetate (pH 8.1), 500 mM KOAc, 150 mM MgOAc) for thirty-five minutes at 94C. Following the Affymetrix protocol, 55 g of fragmented cRNA was hybridized on the Human Hu35KsubA gene chip set and the HuGeneFL array for twenty-four hours at 60 rpm in a 45C hybridization oven. The chips were washed and stained with Streptavidin Phycoerythrin (SAPE) (Molecular Probes) in Affymetrix fluidics stations.

20 To amplify staining, SAPE solution was added twice with an anti-streptavidin biotinylated antibody (Vector Laboratories) staining step in between. Hybridization to the probe arrays was detected by fluorometric scanning (Hewlett Packard Gene Array Scanner). Data was analyzed using Affymetrix GeneChip version 3.0 and Expression Data Mining Tool (EDMT) software (version 1.0).

25 Differential expression of genes between the BPH and normal prostate samples was determined using the Affymetrix Hu35KsubA GeneChip set by the following criteria: (1) For each gene, Affymetrix GeneChip average difference values were determined by standard Affymetrix EDTM software algorithms, which also made "Absent" (=not detected), "Present" (=detected) or "Marginal" (=not clearly Absent or

30 Present) calls for each GeneChip element; (2) all negative values (=Absent) were raised to a floor of +20 (positive 20) so that fold change calculations could be made where values were not already greater than or equal to +20; (3) median levels of expression were compared between the normal control group and the BPH with symptoms disease group to obtain greater than or equal 3-fold up/down values; (4) The median value for



the higher expressing group needed to be greater or equal to 200 average difference units in order to be considered for statistical significance; (5) Genes passing the criteria of #1-4 were analyzed for statistical significance using a two-tailed T test and deemed statistically significant if  $p < 0.05$ .

- 5 AA256268 exhibited a 4.2 fold change in expression levels in tissue from BPH patients with symptoms compared to normal prostate tissue ( $p=0.0015$ ).

### Example 2

#### Cloning of a Full Length Human cDNA Corresponding to the Differentially Expressed mRNA Species

10

The full length human cDNA (SEQ ID NO: 1) corresponding to the differentially expressed mRNA species identified was obtained. Briefly, a pair of gene specific primers were synthesized and a fetal brain cDNA library was screened. Of a number of positive clones obtained, the longest one that corresponded well to the predicted size of the RNA transcript, as determined by Northern blotting, was selected for DNA sequencing.

15

The nucleotide sequences of the full-length human cDNA corresponding to the differentially regulated mRNAs detected above is set forth in SEQ ID NO: 1. The cDNA comprises 4690 base pairs with an open reading frame at nucleotides 406-1845 encoding a protein of 480 amino acids. The corresponding amino acid sequence for the encoded protein is set forth in SEQ ID NO: 2.

20

Analysis of the amino acid sequence of SEQ ID NO: 2 predicts EGF-like domains starting at amino acids 48, 105 and 143; a calcium binding EGF-like domain starting at amino acids 119; an ATP/GTP-binding site motif starting at amino acid 249; and an aspartic acid and asparagine hydroxylation site starting at amino acid 134. A hydrophobicity plot (PEPPLOT) of the amino acid sequence for AA256268 is shown in Figure 5.

25

A Blast of this sequence against the GenBank database indicated that this protein AA256268 had 100% identity with an integrin-binding protein known as Del-1 (GenBank accession number U70312).

30

Figure 1 shows the expression of AA256268 across 31 human samples, including 10 normals, 5 BPH samples from individuals without symptoms, 8 BPH samples from individuals without symptoms who were prostate cancer patients, and 8 BPH samples from patients with symptoms. Upregulation of expression is observed in BPH samples

from people with symptoms as well as in BPH samples from cancer patients. The expression data show that up-regulation of AA256268 is diagnostic for BPH in patients with symptoms.

Figure 2 shows relative AA256268 mRNA levels determined via Northern Blot in a range of normal human tissues. A probe based on SEQ ID NO: 1 (probe F156/R759) was exposed to human mRNA blots (available from ClonTech) overnight at 65C in Church-Gilbert hybridization buffer, following standard methodology as described by Sambrook et al. (1989).

Figure 3 shows an electronic Northern, in which the expression level was measured across a panel of human normal and BPH tissues using the Affymetrix Hu35KsubA GeneChip set. For each tissue type, the mean +/- SDM is shown as a horizontal bar graph for samples obtained from 3 or more normal individuals. The order of expression (high to low) across the normal tissues in Figure 3 is: brain >lung >bone =myometrium >cervix =colon =rectum >small intestine =stomach >endometrium >muscles >ovary >>esophagous >kidney =skin =liver =breast >tonsil >spleen >thymus >>blood. Thus, based upon the tissue panel tested, expression in normal tissue is quite strongly restricted. Because BPH with symptoms is associated with hypertrophic growth of the prostate and/or a low grade chronic inflammation, upregulated expression of AA256268 is likely of diagnostic value in other tissues for disease states involving hypertrophic growth and/or inflammation.

### Example 3

#### Quantitative PCR Analysis of Expression Levels

Figure 4 shows the results of the semi-quantitative PCR analysis of expression levels of mRNA corresponding to SEQ ID NO: 1 in various human tissue samples. Real time PCR detection was accomplished by the use of the ABI PRISM 7700 Sequence Detection System. The 7700 measures the fluorescence intensity of the sample each cycle and is able to detect the presence of specific amplicons within the PCR reaction. Each sample was assayed for the level of GAPDH and mRNA corresponding to SEQ ID NO: 1. GAPDH detection was performed using Perkin Elmer part no. 402869 according to the manufacturer's directions. Primers were designed from SEQ ID NO: 1 using Primer Express®, a program developed by PE, to efficiently find primers and probes for specific sequences. These primers were used in conjunction with SYBR® green (Molecular Probes), a nonspecific double stranded DNA dye, to measure the expression

level mRNA corresponding to SEQ ID NO: 1, which was normalized to the GAPDH level in each sample.

The methods of the invention can be used to distinguish among various types of prostate disease diagnostically and prognostically, or to track disease progress. As shown by the GeneChip® data for the extended patient panel (Figure 1) and the electronic Northern (Figure 3), the nucleic acid sequences corresponding to SEQ ID NO: 1 (DNA and mRNA) are differentially regulated in various prostate diseases, such as BPH. In addition, the nucleic acid sequences corresponding to SEQ ID NO: 1 are differentially expressed among various BPH states compared to normal prostate tissue, such as in patients that have cancer, patients that are symptomatic, and patients that are not symptomatic. Therefore, measuring the total amount of transcript as well as the relative expression level of the gene may be used to stratify patients diagnostically and prognostically.

Although the present invention has been described in detail with reference to examples above, it is understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims. All cited patents, patent applications and publications referred to in this application are herein incorporated by reference in their entirety.

**What Is Claimed:**

1. A method of diagnosing benign prostatic hyperplasia in a patient, comprising determining in a patient sample the level of expression of nucleic acid molecule  
5 encoding a Del-1 protein or a variant thereof.
2. The method of claim 1, wherein the Del-1 protein or the variant thereof is encoded by (a) an isolated nucleic acid molecule that encodes the amino acid sequence of SEQ ID NO: 2; or (b) an isolated nucleic acid molecule which hybridizes to the  
10 complement of a nucleic acid molecule that encodes the amino acid sequence of SEQ ID NO: 2.
3. The method of claim 1 or 2, wherein the patient does not exhibit the symptoms of benign prostatic hyperplasia.  
15
4. A method of identifying binding partners for a Del-1 protein or a variant thereof, comprising:  
exposing said protein to a potential binding partner derived from prostate cells or tissue; and  
20 determining if the potential binding partner binds to said protein, thereby identifying binding partners for the Del-1 protein or the variant thereof.
5. The method of claim 4 wherein the potential binding partner is in a prostate cell extract.  
25
6. The method of claim 5 wherein the cells are obtained from human biopsy samples.
7. The method of claim 4 or 5 wherein the cells are obtained from an animal model  
30 of prostate disease.
8. A method of identifying an agent which modulates the expression of a nucleic acid encoding a Del-1 protein or a variant thereof, comprising:  
exposing prostate cells to the agent; and

determining whether the agent modulates expression of said nucleic acid, thereby identifying an agent which modulates the expression of a nucleic acid encoding the Del-1 protein or the variant thereof.

5     9.     The method of claim 8 wherein the cells are in vitro.

10    10.    The method of claim 8 wherein the cells are obtained from human prostate biopsy tissue.

10    11.    The method of claim 8 wherein the cells are obtained from an animal model of prostate disease.

12.    A method of identifying an agent which modulates at least one activity of a Del-1 protein or a variant thereof, comprising:

15        exposing prostate cells to the agent; and

          determining whether the agent modulates at least one activity of said protein, thereby identifying an agent which modulates at least one activity of the Del-1 protein or the variant thereof.

20    13.    The method of claim 12 wherein the cells are in vitro.

14.    The method of claim 12 wherein the cells are obtained from human prostate biopsy tissue.

25    15.    The method of claim 12 wherein the cells are obtained from an animal model of prostate disease.

16.    The method of any of claims 12-15 wherein said activity is selected from the group consisting of binding to or clustering of endothelial cell receptors of the integrin family, formation of focal complexes, recruitment of talin and vinculin into focal complexes, phosphorylation of proteins within the focal complexes endothelial cell adhesion, endothelial cell migration, angiogenesis and vascular formation.

17.    The method of claim 16 wherein said activity is the binding to or clustering of

endothelial cell receptors of the integrin family.

18. The method of claim 17 [wherein said endothelial cell receptors of the integrin family are  $\alpha\beta v3$  receptors.


5


19. The method of claim 16 wherein said activity is the phosphorylation of p125<sup>FAK</sup>, MAPK or Shc.

20. A method of modulating the expression of a nucleic acid encoding a Del-1  
10 protein or a variant thereof, in a subject with benign prostatic hyperplasia, comprising:  
administering to the subject an effective amount of an agent which modulates the  
expression of a nucleic acid encoding the Del-1 protein or the variant thereof.

21. A method of modulating at least one activity of a Del-1 protein or a variant  
15 thereof, in a subject with benign prostatic hyperplasia, comprising:  
administering to the subject an effective amount of an agent which modulates at  
least one activity of the Del-1 protein or the variant thereof.


20






#1505583<1-WA>





#1505583<1-WA>



## Sequence Listing

<110> Munger, William E.  
 Kulkarni, Prakash  
 Getzenberg, Robert H.

<120> Del-1 and Benign Prostatic Hyperplasia

<130> 44921-5035-PR

<140>  
 <141>

<150> US 60/245,674  
 <151> 2000-11-06

<160> 2

<170> PatentIn Ver. 2.1

<210> 1  
 <211> 4690  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (406)..(1845)  
 <223> Clone no. AA256268

<400> 1  
 gccgcgcgcg agaacagcga cagccgagcg cccgggtccgc ctgtctgccg gtgggtctgc 60  
 tgccccgcgc agcagacccg gggcggccgc gggagcccg gccccgccg ccgcgcctct 120  
 gccgggaccc acccgagcgc gagggctgag cccgccggcg gctccccgga gtcacccac 180  
 ctccgcgcgc cggagcgcag gcaaaagggg aggaaaggct cctctcttta gtcaccactc 240  
 tcgccctctc caagaatttg ttaacaaaag cgctgaggaa agagaacgtc ttcttgaatt 300  
 ctttagtagg ggcggagtct gctgctgccc tgcgctgcca cctcggtac actgcccctcc 360  
 gcgacgaccc ctgaccagcc ggggtcacgt ccgggagacg ggatc atg aag cgc tcg 417  
 Met Lys Arg Ser  
 1  
 gta gcc gtc tgg ctc ttg gtc ggg ctc agc ctc ggt gtc ccc cag ttc 465  
 Val Ala Val Trp Leu Leu Val Gly Leu Ser Leu Gly Val Pro Gln Phe  
 5 10 15 20  
 ggc aaa ggt gat att tgt gat ccc aat cca tgt gaa aat gga ggt atc 513  
 Gly Lys Gly Asp Ile Cys Asp Pro Asn Pro Cys Glu Asn Gly Gly Ile  
 25 30 35  
 tgt ttg cca gga ttg gct gat ggt tcc ttt tcc tgt gag tgt cca gat 561  
 Cys Leu Pro Gly Leu Ala Asp Gly Ser Phe Ser Cys Glu Cys Pro Asp  
 40 45 50  
 ggc ttc aca gac ccc aac tgt tct agt gtt gtg gag gtt gca tca gat 609  
 Gly Phe Thr Asp Pro Asn Cys Ser Ser Val Val Glu Val Ala Ser Asp

55	60	65	
gaa gaa gaa cca act tca gca ggt ccc tgc act cct aat cca tgc cat Glu Glu Glu Pro Thr Ser Ala Gly Pro Cys Thr Pro Asn Pro Cys His 70 75 80			657
aat gga gga acc tgt gaa ata agt gaa gca tac cga ggg gat aca ttc Asn Gly Gly Thr Cys Glu Ile Ser Glu Ala Tyr Arg Gly Asp Thr Phe 85 90 95 100			705
ata ggc tat gtt tgt aaa tgt ccc cga gga ttt aat ggg att cac tgt Ile Gly Tyr Val Cys Lys Cys Pro Arg Gly Phe Asn Gly Ile His Cys 105 110 115			753
cag cac aac ata aat gaa tgc gaa gtt gag cct tgc aaa aat ggt gga Gln His Asn Ile Asn Glu Cys Glu Val Glu Pro Cys Lys Asn Gly Gly 120 125 130			801
ata tgt aca gat ctt gtt gct aac tat tcc tgt gag tgc cca ggc gaa Ile Cys Thr Asp Leu Val Ala Asn Tyr Ser Cys Glu Cys Pro Gly Glu 135 140 145			849
ttt atg gga aga aat tgt caa tac aaa tgc tca ggc cca ctg gga att Phe Met Gly Arg Asn Cys Gln Tyr Lys Cys Ser Gly Pro Leu Gly Ile 150 155 160			897
gaa ggt gga att ata tca aac cag caa atc aca gct tcc tct act cac Glu Gly Gly Ile Ile Ser Asn Gln Gln Ile Thr Ala Ser Ser Thr His 165 170 175 180			945
cga gct ctt ttt gga ctc caa aaa tgg tat ccc tac tat gca cgt ctt Arg Ala Leu Phe Gly Leu Gln Lys Trp Tyr Pro Tyr Tyr Ala Arg Leu 185 190 195			993
aat aag aag ggg ctt ata aat gcg tgg aca gct gca gaa aat gac aga Asn Lys Lys Gly Leu Ile Asn Ala Trp Thr Ala Ala Glu Asn Asp Arg 200 205 210			1041
tgg ccg tgg att cag ata aat ttg caa agg aaa atg aga gtt act ggt Trp Pro Trp Ile Gln Ile Asn Leu Gln Arg Lys Met Arg Val Thr Gly 215 220 225			1089
gtg att acc caa gga gcc aag agg att gga agc cca gag tat ata aaa Val Ile Thr Gln Gly Ala Lys Arg Ile Gly Ser Pro Glu Tyr Ile Lys 230 235 240			1137
tcc tac aaa att gcc tac agt aat gat gga aag act tgg gca atg tac Ser Tyr Lys Ile Ala Tyr Ser Asn Asp Gly Lys Thr Trp Ala Met Tyr 245 250 255 260			1185
aaa gtg aaa ggc acc aat gaa gac atg gtg ttt cgt gga aac att gat Lys Val Lys Gly Thr Asn Glu Asp Met Val Phe Arg Gly Asn Ile Asp 265 270 275			1233
aac aac act cca tat gct aac tct ttc aca ccc ccc ata aaa gct cag Asn Asn Thr Pro Tyr Ala Asn Ser Phe Thr Pro Pro Ile Lys Ala Gln 280 285 290			1281
tat gta aga ctc tat ccc caa gtt tgt cga aga cat tgc act ttg cga Tyr Val Arg Leu Tyr Pro Gln Val Cys Arg Arg His Cys Thr Leu Arg 295 300 305			1329

atg gaa ctt ctt ggc tgt gaa ctg tcg ggt tgt tct gag cct ctg ggt 1377  
 Met Glu Leu Leu Gly Cys Glu Leu Ser Gly Cys Ser Glu Pro Leu Gly  
 310 315 320

atg aaa tca gga cat ata caa gac tat cag atc act gcc tcc agc atc 1425  
 Met Lys Ser Gly His Ile Gln Asp Tyr Gln Ile Thr Ala Ser Ser Ile  
 325 330 335 340

ttc aga acg ctc aac atg gac atg ttc act tgg gaa cca agg aaa gct 1473  
 Phe Arg Thr Leu Asn Met Asp Met Phe Thr Trp Glu Pro Arg Lys Ala  
 345 350 355

cgg ctg gac aag caa ggc aaa gtg aat gcc tgg acc tct ggc cac aat 1521  
 Arg Leu Asp Lys Gln Gly Lys Val Asn Ala Trp Thr Ser Gly His Asn  
 360 365 370

gac cag tca caa tgg tta cag gtg gat ctt ctt gtt cca acc aaa gtg 1569  
 Asp Gln Ser Gln Trp Leu Gln Val Asp Leu Leu Val Pro Thr Lys Val  
 375 380 385

act ggc atc att aca caa gga gct aaa gat ttt ggt cat gta cag ttt 1617  
 Thr Gly Ile Ile Thr Gln Gly Ala Lys Asp Phe Gly His Val Gln Phe  
 390 395 400

gtt ggc tcc tac aaa ctg gct tac agc aat gat gga gaa cac tgg act 1665  
 Val Gly Ser Tyr Lys Leu Ala Tyr Ser Asn Asp Gly Glu His Trp Thr  
 405 410 415 420

gta tac cag gat gaa aag caa aga aaa gat aag gtt ttc cag gga aat 1713  
 Val Tyr Gln Asp Glu Lys Gln Arg Lys Asp Lys Val Phe Gln Gly Asn  
 425 430 435

ttt gac aat gac act cac aga aaa aat gtc atc gac cct ccc atc tat 1761  
 Phe Asp Asn Asp Thr His Arg Lys Asn Val Ile Asp Pro Pro Ile Tyr  
 440 445 450

gca cga cac ata aga atc ctt cct tgg tcc tgg tac ggg agg atc aca 1809  
 Ala Arg His Ile Arg Ile Leu Pro Trp Ser Trp Tyr Gly Arg Ile Thr  
 455 460 465

ttg cgg tca gag ctg ctg ggc tgc aca gag gag gaa tgaggggagg 1855  
 Leu Arg Ser Glu Leu Leu Gly Cys Thr Glu Glu Glu  
 470 475 480

ctacatttca caaccctctt ccctatttcc ctaaaagtat ctccatggaa tgaactgtgc 1915  
 aaaatctgta ggaaactgaa tggttttttt tttttttttc atgaaaaagt gctcaaatta 1975  
 tggtaggcaa ctaacggtgt ttttaagggg gtctaagcct gccttttcaa tgatttaatt 2035  
 tgattttatt ttatccgtca aatctcttaa gtaacaacac attaatgtgtg aattactttt 2095  
 ctctcattgt ttctgaatt attcgcattg gtagaaatat attagggaaa gaaagtagcc 2155  
 ttcttttttat agcaagagta aaaaagtctc aaagtcacaa aataagagca agagttgata 2215  
 gagctttttac aatcaatact cacctaattc tgataaaagg aatactgcaa tgtagcaat 2275  
 aagttttttt cttctgtaat gactctacgt tatectgttt ccctgtgcct accaaacact 2335

gtcaatgttt attacaaaat tttaaagaag aatatgtaac atgcagtact gatattataa 2395  
ttctcatttt actttcatta ttctataata gagattatgt gacttccttt tcttttagtt 2455  
ctattctaca ttcttaatat tgtatattac ctgaataatt caattttttt ctaattgaat 2515  
ttcctattag ttgactaaaa gaagtgtcat gtttactcat atatgtagaa catgactgcc 2575  
tatcagtaga ttgatctgta tttaatatcc gttaattaaa tctgcagttt tatttttgaa 2635  
ggaagccata actattttaat ttccaaataa ttgcttcata aagaatccca tactctcagt 2695  
ttgcacaaaa gaacaaaaaa tatatatgtc tctttaaatt taaatcttca tttagatggg 2755  
aattacatat ccttatattt actttaaaaa atcggttat ttgtttattt tataaaaaat 2815  
ttagcaaaga aatattaata tagtgctgca tagttcgggc aagcatactc atcatttctt 2875  
tggtcagctc cacatttcct gtgaaactaa catcttattg agatttgaaa ctgggtggtag 2935  
tttcccagga aggcacaggt ggagttattt gtgagaagca aagtgtttac taatgacaaa 2995  
gtagtaaacc attttcaaga tgaaaactga ttctatttta ttttgcttca aaggctctga 3055  
aaaaataagc aattatcata acaatttggt attgatactg gaggtttcat tgacatgtct 3115  
ctcaaattaa agctcacact gcctccataa aagtcttcaa catctaattt ataagcttta 3175  
caagtattta ttttataagg cttagacaga attattggag ttttaaatta agtgtattgg 3235  
aaaagaaagg atggtatgtg tatgaaatgt taagatccta cgcaacactg ctattttttt 3295  
cctttaatat ttgtgctgca taacaaaagc cactagactg ttactgtctt gtctgtccat 3355  
gtgttaacag catttcttaa tgatgtatat atggagtggg cttcaatcat agtgaagaat 3415  
ttaagagaa agtcaattgt attggcattt ttaataagaa caaaattagt tcgtctaagg 3475  
ggactggctg gccacatatt tgttccttgc ccatatgctt tctacttctt gttcttatta 3535  
tgaaattatg aatttgaagc ctctgaaatg gtgatcagtt ttcaacatct ttcaaaaaaca 3595  
aaattactat ttctccata ttgcctttt tagataactt taaagttagg attttaaaat 3655  
atttgtaact ggctaaattt taaagtcgtg acaaataatt acttaggttc agaaatatac 3715  
acacacttac tctttagcca gtttcttca aggtttactg tcccatcaga tatctagcca 3775  
tttctcttg caaattacat accttcttaa gagtgtattt ttaagattat tacttatgct 3835  
ttatgatgat atagtttttc aaaattattt atagcttcat atgatgtttt gtaatttttt 3895  
ctattgatac ctgttttaaa aatattttcc aaggaagttg attaaaatta tatttggttac 3955  
cttttagaaa aagcattgaa atgagtttct cttgcttttt cattttccct ctgctttata 4015  
tgctcttcgc aatacatcat gtccaacggg atacctattg ttctcatgac acccaaaatt 4075  
gatgagagca aaggggtcgc accatatgga aatggtgaaa actattgtaa agtagtatta 4135  
tgaagtagct tttgtgtcat tcatgtcgat gacatgaaag tgaagtaaatt ttattctatg 4195

```
<210> 2
<211> 480
<212> PRT
<213> Homo sapiens
```

```

<400> 2
Met Lys Arg Ser Val Ala Val Trp Leu Leu Val Gly Leu Ser Leu Gly
      5                      10                      15

Val Pro Gln Phe Gly Lys Gly Asp Ile Cys Asp Pro Asn Pro Cys Glu
      20                      25                      30

Asn Gly Gly Ile Cys Leu Pro Gly Leu Ala Asp Gly Ser Phe Ser Cys
      35                      40                      45

Glu Cys Pro Asp Gly Phe Thr Asp Pro Asn Cys Ser Ser Val Val Glu
      50                      55                      60

Val Ala Ser Asp Glu Glu Glu Pro Thr Ser Ala Gly Pro Cys Thr Pro
      65                      70                      75                      80

Asn Pro Cys His Asn Gly Gly Thr Cys Glu Ile Ser Glu Ala Tyr Arg
      85                      90                      95

Gly Asp Thr Phe Ile Gly Tyr Val Cys Lys Cys Pro Arg Gly Phe Asn
      100                     105                     110

Gly Ile His Cys Gln His Asn Ile Asn Glu Cys Glu Val Glu Pro Cys
      115                     120                     125

Lys Asn Gly Gly Ile Cys Thr Asp Leu Val Ala Asn Tyr Ser Cys Glu
      130                     135                     140

Cys Pro Gly Glu Phe Met Gly Arg Asn Cys Gln Tyr Lys Cys Ser Gly
      145                     150                     155                     160

Pro Leu Gly Ile Glu Gly Gly Ile Ile Ser Asn Gln Gln Ile Thr Ala
      165                     170                     175

Ser Ser Thr His Arg Ala Leu Phe Gly Leu Gln Lys Trp Tyr Pro Tyr
      180                     185                     190

```

Tyr Ala Arg Leu Asn Lys Lys Gly Leu Ile Asn Ala Trp Thr Ala Ala  
 195 200 205  
 Glu Asn Asp Arg Trp Pro Trp Ile Gln Ile Asn Leu Gln Arg Lys Met  
 210 215 220  
 Arg Val Thr Gly Val Ile Thr Gln Gly Ala Lys Arg Ile Gly Ser Pro  
 225 230 235 240  
 Glu Tyr Ile Lys Ser Tyr Lys Ile Ala Tyr Ser Asn Asp Gly Lys Thr  
 245 250 255  
 Trp Ala Met Tyr Lys Val Lys Gly Thr Asn Glu Asp Met Val Phe Arg  
 260 265 270  
 Gly Asn Ile Asp Asn Asn Thr Pro Tyr Ala Asn Ser Phe Thr Pro Pro  
 275 280 285  
 Ile Lys Ala Gln Tyr Val Arg Leu Tyr Pro Gln Val Cys Arg Arg His  
 290 295 300  
 Cys Thr Leu Arg Met Glu Leu Leu Gly Cys Glu Leu Ser Gly Cys Ser  
 305 310 315 320  
 Glu Pro Leu Gly Met Lys Ser Gly His Ile Gln Asp Tyr Gln Ile Thr  
 325 330 335  
 Ala Ser Ser Ile Phe Arg Thr Leu Asn Met Asp Met Phe Thr Trp Glu  
 340 345 350  
 Pro Arg Lys Ala Arg Leu Asp Lys Gln Gly Lys Val Asn Ala Trp Thr  
 355 360 365  
 Ser Gly His Asn Asp Gln Ser Gln Trp Leu Gln Val Asp Leu Leu Val  
 370 375 380  
 Pro Thr Lys Val Thr Gly Ile Ile Thr Gln Gly Ala Lys Asp Phe Gly  
 385 390 395 400  
 His Val Gln Phe Val Gly Ser Tyr Lys Leu Ala Tyr Ser Asn Asp Gly  
 405 410 415  
 Glu His Trp Thr Val Tyr Gln Asp Glu Lys Gln Arg Lys Asp Lys Val  
 420 425 430  
 Phe Gln Gly Asn Phe Asp Asn Asp Thr His Arg Lys Asn Val Ile Asp  
 435 440 445  
 Pro Pro Ile Tyr Ala Arg His Ile Arg Ile Leu Pro Trp Ser Trp Tyr  
 450 455 460  
 Gly Arg Ile Thr Leu Arg Ser Glu Leu Leu Gly Cys Thr Glu Glu Glu  
 465 470 475 480



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ ~~BLACK BORDERS~~
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ ~~COLOR OR BLACK AND WHITE PHOTOGRAPHS~~
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**